BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005

Reuters
19 Dec 2024
BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005

Dec 19 (Reuters) - Alumis Inc ALMS.O:

  • ALUMIS ANNOUNCES POSITIVE PHASE 1 DATA FOR CNS PENETRANT TYK2 INHIBITOR, A-005

  • A-005 WAS WELL TOLERATED AND DEMONSTRATED ABILITY TO CROSS BLOOD-BRAIN BARRIER

  • DATA SUPPORT ADVANCEMENT TO PHASE 2 CLINICAL TRIAL IN MULTIPLE SCLEROSIS, ANTICIPATED IN 2H 2025

  • MAXIMAL TYK2 INHIBITION ACHIEVED WITH FAVORABLE PHARMACOKINETIC PROFILE IN CNS AND PERIPHERY

Source text: ID:nGNX8y7dPY

Further company coverage: ALMS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10